1. UNAIDS. Progress towards the Start Free, Free S, Free AIDS. targets. 2020. https://www.unaids.org/en/resources/documents/2020/start-free-stay-free-aids-free-2020-progress-report.
2. Delany-Moretlwe S, Hughes J, Bock P, Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. Paper presented at: HIV R4P;, Virtual et al. https://programme.hivr4p.org/Abstract/Abstract/1479.
3. Republic of South Africa Department of Health. National policy on HIV pre-exposure prophylaxis (PrEP) and test and treat (T&T). 2016. http://www.sahivsoc.org/Files/PREP%20and%20TT%20Policy%20-%20Final%20Draft%20-%205%20May%202016%20(HIV%20news).pdf.
4. HIV Prevention Trials Network. HPTN 084 study demonstrates superiority of CAB LA to oral TDF/FTC for the prevention of HIV. 2020. https://www.hptn.org/news-and-events/press-releases/hptn-084-study-demonstrates-superiority-of-cab-la-to-oral-tdfftc-for.
5. Krovi SA, Johnson LM, Luecke E, Achilles SL, van der Straten A. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention. Adv Drug Del Rev. 2021;176:113849.